Search

Genmab A-S

Cerrado

2,022 0.15

Resumen

Variación precio

24h

Actual

Mínimo

2006

Máximo

2042

Métricas clave

By Trading Economics

Ingresos

243M

295M

Ventas

259M

1.2B

P/B

Media del Sector

24.245

57.002

BPA

34.85

Margen de beneficios

25.541

Empleados

3,119

EBITDA

216M

431M

Recomendaciones

By TipRanks

Recomendaciones

Neutral

Estimación a 12 Meses

-1.49% downside

Dividendos

By Acuity

Próximas Ganancias

5 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

11B

124B

Apertura anterior

2021.85

Cierre anterior

2022

Genmab A-S Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

13 ago 2026, 23:56 UTC

News

Molson Coors Beverage Co shares advanced in after-market hours to $43.20, following Q2 revenues of $3.10 billion that met analyst expectations.

13 ago 2026, 23:56 UTC

GitLab Inc. shares are trading lower in after-market hours, despite an earlier rebound from session lows. No specific news was identified.

13 ago 2026, 23:56 UTC

Pegasystems Inc. shares are lower in after-market trading, with no specific news identified. The broader market reacts to rising initial jobless claims.

13 ago 2026, 23:56 UTC

Zebra Technologies shares are trading higher in after-market hours, maintaining strength above its 20-day moving average and near the upper end of its one-month range.

13 ago 2026, 23:56 UTC

Correlated Moves

T Rowe Price Group Inc shares are lower in after-market trading, extending a trend of declines over the past three sessions amid broader market weakness.

13 ago 2026, 23:56 UTC

iShares TIPS Bond ETF traded roughly flat during after-market hours. The asset remains near the lower end of its one-month trading range.

13 ago 2026, 23:56 UTC

Cherry Hill Mortgage Investment Corp is trading lower in after-market hours, declining from earlier gains despite remaining above its 20-day moving average.

13 ago 2026, 23:56 UTC

Toast Inc shares are lower in after-market trading. No specific company news was identified to explain this price movement.

13 ago 2026, 23:56 UTC

Correlated Moves

Skyworks Solutions Inc shares declined in after-market trading, influenced by broader market movements and rising initial jobless claims indicating potential labor market softness.

13 ago 2026, 23:56 UTC

Shares of Camtek Ltd are trading higher in after-market hours, remaining above their 20-day moving average despite routine performance during the regular session.

13 ago 2026, 23:56 UTC

NetApp Inc. shares are higher in after-market trading, remaining above their 20-day moving average amid broader market dynamics and rising initial jobless claims.

13 ago 2026, 23:56 UTC

Correlated Moves

TPG Inc shares declined in after-market trading, settling lower after earlier gains. The drop aligns with a slight decrease in the Russell 2000 Index.

13 ago 2026, 23:56 UTC

News
Event

Bristol-Myers Squibb's shares are lower after FDA approval of ZENBEXUS for multiple myeloma, amid concerns over drug risks and ongoing trial verification.

13 ago 2026, 23:56 UTC

Correlated Moves
Macro News
ETF Constituents

iShares MSCI South Korea ETF gains in after-market trading, reflecting KOSPI's surge amid positive sentiment around interest rates and U.S. stock performance.

13 ago 2026, 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

13 ago 2026, 23:51 UTC

Tyler Technologies Inc shares are higher in after-market trading, reflecting strong performance since Thursday's close, despite no specific news identified to explain the movement.

13 ago 2026, 23:51 UTC

Clean Energy Fuels Corp shares are lower in after-market hours, reversing earlier gains amid broader market sentiment influenced by recent economic data.

13 ago 2026, 23:51 UTC

Gladstone Land Corp. shares rose in after-market trading, recovering from earlier losses amid broader market optimism following unchanged producer price index data.

13 ago 2026, 23:51 UTC

L3Harris Technologies Inc. shares are higher in after-hours trading, reflecting positive market sentiment amid decreased expectations for a Federal Reserve interest rate hike.

13 ago 2026, 23:51 UTC

StoneX Group Inc shares are lower in after-market hours, with no specific news identified. The asset remains near the lower end of its one-month trading range.

13 ago 2026, 23:51 UTC

Asia equity markets show mixed performance as Japan's Nikkei rises on tech optimism and potential rate hikes, while China's Shanghai Composite dips amid geopolitical tensions and falling oil prices; U.S. jobless claims exceed expectations, softening inflation outlook.

13 ago 2026, 23:51 UTC

Global equity markets rise, led by U.S. mega-caps, while mixed economic signals emerge from jobless claims and inflation data.

13 ago 2026, 23:51 UTC

Mixed trading in European equities as UK GDP growth exceeds expectations while industrial production shows weakness amidst fluctuating oil prices and trade balance concerns.

13 ago 2026, 23:51 UTC

U.S. equity indices remain flat as investors weigh mixed economic signals, rising jobless claims, and easing inflation amid geopolitical tensions and falling oil prices.

13 ago 2026, 23:51 UTC

Australia's Westpac Consumer Confidence Report Set for August 18 Amidst Cautious Market Sentiment and Inflation Concerns.

13 ago 2026, 23:51 UTC

Michigan Consumer Sentiment Report Set for August 14, Forecasted at 54.5 Amid Cautious Optimism Following Stable Inflation Data

13 ago 2026, 23:51 UTC

US Business Inventories MoM data for June 2026 set to release on August 14, with a modest increase of 0.1% anticipated amid cautious market sentiment and inflation concerns.

13 ago 2026, 23:51 UTC

Cautious Market Awaits July 2026 Building Permits Data Amid Ongoing Construction Sector Weakness and Rising Costs

13 ago 2026, 23:51 UTC

NIO Inc shares are higher in after-market trading, reflecting broader market trends amid unchanged producer prices and reduced interest rate hike expectations.

13 ago 2026, 23:51 UTC

Digital Realty Trust Inc shares are higher in after-market trading, reflecting broader market optimism following recent economic data and a recovery from earlier lows.

Comparación entre iguales

Cambio de precio

Genmab A-S previsión

Precio Objetivo

By TipRanks

-1.49% descenso

Estimación a 12 Meses

Media 2,493.35 DKK  -1.49%

Máximo 3,320 DKK

Mínimo 308.417 DKK

De acuerdo con 7 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Genmab A-S Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

7 ratings

3

Comprar

2

Mantener

2

Vender

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Genmab A-S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
help-icon Live chat